Neurocrine Biosciences, Inc.
MX ˙ BMV ˙ US64125C1099
SecurityMX:NBIX / Neurocrine Biosciences, Inc.
InstitutionClearbridge Investments, LLC
Latest Disclosed Ownership310,035 shares
Latest Disclosed Value $ 40,844,011
Clearbridge Investments, LLC reports 0.01% decrease in ownership of NBIX / Neurocrine Biosciences, Inc.

On May 13, 2026 - Clearbridge Investments, LLC filed a 13F-HR form disclosing ownership of 310,035 shares of Neurocrine Biosciences, Inc. (MX:NBIX) valued at $40,844,011 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 11, 2026 disclosing 310,077 shares of Neurocrine Biosciences, Inc.. This represents a change in shares of -0.01% during the quarter.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-13 2026-03-31 13F Neurocrine Biosciences COM 64125C109 310,035 -42 -0.01 40,844 -7.13 0.0320
2026-02-11 2025-12-31 13F Neurocrine Biosciences COM 64125C109 310,077 -26,859 -7.97 43,978 -7.02 0.0352
2025-11-13 2025-09-30 13F Neurocrine Biosciences COM 64125C109 336,936 -5,366 -1.57 47,299 9.94 0.0356
2025-08-12 2025-06-30 13F Neurocrine Biosciences COM 64125C109 342,302 0 0.00 43,024 13.64 0.0349
2025-05-13 2025-03-31 13F Neurocrine Biosciences COM 64125C109 342,302 23,003 7.20 37,859 -13.14 0.0331
2025-02-12 2024-12-31 13F Neurocrine Biosciences COM 64125C109 319,299 0 0.00 43,584 18.47 0.0353
2024-11-12 2024-09-30 13F Neurocrine Biosciences COM 64125C109 319,299 -21,503 -6.31 36,790 -21.59 0.0289
2024-08-27 2024-06-30 13F/A-1 Neurocrine Biosciences COM 64125C109 340,802 0 0.00 46,918 -0.18 0.0381
2024-08-14 2024-06-30 13F Neurocrine Biosciences COM 64125C109 340,802 0 46,918 0.0384
2024-05-13 2024-03-31 13F Neurocrine Biosciences COM 64125C109 340,802 0 0.00 47,003 4.67 0.0373
2024-02-09 2023-12-31 13F Neurocrine Biosciences COM 64125C109 340,802 28,805 9.23 44,904 27.94 0.0386
2023-11-13 2023-09-30 13F Neurocrine Biosciences COM 64125C109 311,997 0 0.00 35,100 19.30 0.0338
2023-08-11 2023-06-30 13F Neurocrine Biosciences COM 64125C109 311,997 61,210 24.41 29,421 15.90 0.0266
2023-05-12 2023-03-31 13F Neurocrine Biosciences COM 64125C109 250,787 0 0.00 25,385 -15.25 0.0243
2023-02-10 2022-12-31 13F Neurocrine Biosciences COM 64125C109 250,787 0 0.00 29,954 12.45 0.0296
2022-11-14 2022-09-30 13F Neurocrine Biosciences COM 64125C109 250,787 0 0.00 26,636 8.95 0.0269
2022-08-11 2022-06-30 13F Neurocrine Biosciences COM 64125C109 250,787 -5 -0.00 24,447 3.98 0.0228
2022-05-13 2022-03-31 13F Neurocrine Biosciences COM 64125C109 250,792 0 0.00 23,512 10.07 0.0177
2022-02-11 2021-12-31 13F Neurocrine Biosciences COM 64125C109 250,792 -1,058 -0.42 21,360 -11.57 0.0145
2021-11-12 2021-09-30 13F Neurocrine Biosciences COM 64125C109 251,850 -50 -0.02 24,155 -1.47 0.0172
2021-08-13 2021-06-30 13F Neurocrine Biosciences COM 64125C109 251,900 -40 -0.02 24,515 0.06 0.0171
2021-05-13 2021-03-31 13F Neurocrine Biosciences COM 64125C109 251,940 40,410 19.10 24,501 20.84 0.0183
2021-02-10 2020-12-31 13F Neurocrine Biosciences COM 64125C109 211,530 -7,970 -3.63 20,275 -3.94 0.0157
2020-11-12 2020-09-30 13F Neurocrine Biosciences COM 64125C109 219,500 219,500 21,107 0.0181
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.